Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 10/20 | 0.74 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.52 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.49 |
| ▸ | P2RX5 | Q93086 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25171689 | 0.85 | P2RX4 (1.00) | P2RX4P2RX7P2RX2P2RX5ALDH1A1 | |
| SCHEMBL11246611 | 0.74 | KMT2A (0.43) | P2RX4ALDH1A1LMNACA12CA9 | |
| SCHEMBL4628719 | 0.73 | SMN1; SMN2 (0.53) | P2RX4P2RX7ALDH1A1LMNACNR2 | |
| SCHEMBL4629412 | 0.72 | P2RX4 (0.56) | P2RX4P2RX7P2RX2P2RX5ALDH1A1 | |
| SCHEMBL25168562 | 0.71 | P2RX4 (0.74) | P2RX4P2RX7P2RX2P2RX5ALDH1A1 | |
| SCHEMBL28333322 | 0.70 | CNR2 (0.65) | P2RX4P2RX7P2RX2P2RX5ALDH1A1 | |
| SCHEMBL25168617 | 0.69 | P2RX7 (1.00) | P2RX4P2RX7P2RX2P2RX5ALDH1A1 | |
| SCHEMBL11050475 | 0.69 | ALDH1A1 (0.48) | P2RX4ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL4628698 | 0.68 | P2RX7 (0.54) | P2RX4P2RX7P2RX2P2RX5ALDH1A1 | |
| SCHEMBL4629443 | 0.68 | P2RX7 (0.53) | P2RX4P2RX7P2RX2P2RX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | P2RX4 2333/4885P2RX7 1894/4885P2RX2 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.